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Abstract
Immunotherapy has improved patient outcomes in advanced or metastatic settings across a number
of cancers. Patients with tumours deficient in the DNA mismatch repair (DNA-MMR) pathway
often show high response rates to immune checkpoint inhibitors (ICIs) with a rise in immune
surveillance. However, little is known about the immune sensitization effects of inducing DNAMMR-deficiency in low tumour mutational burden (TMB) cancers, such as ICI refractory
neuroblastoma. In addition, the dynamic T-cell profile that results from such a DNA-MMR
inactivation, and whether this may confer a therapeutic benefit, is poorly understood. Here, I used
CRISPR/CAS9 genome editing technology to knock out (KO) MLH1, a crucial molecule in the
DNA-MMR pathway, in mouse neuroblastoma (neuro-2a) cells – a low TMB pediatric cancer
refractory to ICIs – to induce MMR deficiency. To analyze tumour growth inhibition in response
to ICIs and immunophenotype the tumour-infiltrating lymphocytes (TILs), tumours with intact or
induced MMR deficiency were injected subcutaneously into immunocompetent mice. Tumour
growth were measured after treatment with anti-PD1 antibodies and TILs were analyzed for
activation, exhaustion, and effector markers, allowing for an in-depth flow cytometric analysis of
T-cell subsets in these tumours. This study shows that inducing MMR-deficiency induces a robust
anti-tumour response in a low TMB cancer. Moreover, this sensitization was accompanied by
specific phenotypic changes of T-cells in response to anti-PD1 therapy in the tumour.
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Summary for Lay Audience
Immunotherapy is a new form of cancer treatment that utilizes the immune system to recognize
and kill cancer cells. In this thesis, I focus on immune checkpoint inhibitors (ICIs), which is a form
of cancer immunotherapy that binds to “immune checkpoints” found on immune cells. These
immune checkpoints typically serve to tamper down the immune response in order to prevent a
harmful overactivation of the immune system. ICIs therefore bind to immune checkpoint
molecules, blocking them from exerting their function, which then allows for immune cells to
become re-invigorated and target cancer cells. Over the past few years, clinical trials have shown
that a number of patients that are treated with immunotherapy have a long-term response to
treatment. Moreover, responders to ICIs often have a very high number of mutations in their
tumours. A subset of cancer patients that show a favorable response to ICIs are cancer patients that
have a deficiency in their ability to repair DNA mistakes, which results in a large number of
mutations in their tumour. Unfortunately, many cancer patients with a low number of tumour
mutations do not respond to ICIs. In this thesis, I studied the effect of inducing a deficiency of
DNA repair in a tumour with a low number of mutations and hypothesized that this would result
in an increase in mutations in the tumour and a better response to ICIs.
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Chapter 1
Introduction
1.1 – Cancer and the immune system
1.1.1 Cancer and the immune system
Cancer is a disease in which cells divide uncontrollably and no longer abide by typical
growth-control mechanisms 1. Cancer cells are transformed “normal cells” that
progressively mutate and evolve to continuously proliferate and can ultimately spread to
other organs and kill the host2. More recently, it has become apparent that the immune
system plays a critical role in the development and control of tumours. The term “cancer
immunoediting” has been coined to describe the role that the immune system plays in both
limiting and promoting tumour growth3. Immunoediting involves three stages: elimination,
equilibrium and escape3. In the first phase, elimination, both the innate and adaptive
components of the immune system work together to eliminate tumour cells before they are
clinically detectable4. This is likely a reasonably effective process, as many individuals do
not develop clinically detectable cancer in their lifetimes. In the equilibrium phase, the
tumour and the immune system reach an equilibrium where the immune system is able to
control tumour growth, but not completely eliminate all tumour cells. The immune system
is therefore able to keep the net number of cancer cells constant or at a number below that
necessary to generate detectable tumours during equilibrium5. While this prevents the
tumour from forming clinically detectable disease, certain cancer cells that escape the
elimination phase remain alive, as immune selection and pressure favours cells with lower
immunogenicity6. In the escape phase, the immune system is no longer able to suppress
tumour growth as some tumour cells generate mutations that mediate resistance to immune
control. This results in the clinical presentation of the disease4. As all tumours go through
the process of immunoediting, clinically detectable tumours are commonly resistant to
immune control and either evade or actively suppress anti-tumour immunity.
1.1.2 Role of the adaptive immune system in anti-tumour immunity
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Innate immunity is the first barrier of defense in the fight against foreign pathogens. The
innate immune system is activated rapidly after detection of a pathogen; however, it does
not develop a pathogen-specific response or immunological memory against the foreign
entity. Adaptive immunity, on the other hand, is capable of mounting a specific response
tailored to the invading pathogen or neoplastic cells. Adaptive immunity is also responsible
for immunological memory against pathogens and tumours7. This highlights the
significance of adaptive immunity in targeting cancer in a sustainable manner.

Adaptive immunity consists of T-cells and B-cells and, unlike innate immunity, is antigenspecific. Antigens (antibody generators) are molecules that can stimulate an immune
response in the body3. This type of immunity is quite powerful because it targets cancer
cells on the basis of recognition of tumour-specific and/or tumour-associated antigens and
stimulates immunological memory to continuously recognize and eradicate tumour cells
expressing those antigens 8. Antigen-specific recognition is due to the generation of a vast
number of possible receptors found on T-cells (TCRs) and B-cells (BCRs)8. Collectively,
these cells are able to recognize a large number of unique antigen-specific peptides due to
their VD(J) recombination9. This genetic recombination takes place between variable,
diversity, and joining segments of TCRs or BCRs, which allows for the generation of
millions of different unique and specific receptors9. B-cells and T-cells recognize foreign
antigens and in the context of pro-inflammatory cytokines are able to mount a proper
antigen-specific clonal response to neutralize the threat8. Importantly, T-cells recognize
only foreign antigens that are presented on MHC molecules while B-cell responses are
MHC-independent8. Conventional T-cells are divided into two different types: CD4+ Tcells and CD8+ T-cells. CD4+ T-cells recognize peptides bound to MHC-II molecules,
which are present only on antigen-presenting cells. Such peptides or neopeptides (“new
peptides”) can arise from mutated proteins that go on to be detected as a “non-self”
protein10. Once the CD4+ T-cell is bound to MHC-II, it can differentiate into either a Thelper cell or a T-regulatory cell (Treg), depending on the cytokine context. T-helper cells,
as their name suggest, aid in the activation of NK cells, B-cells and CD8+ T-cells. However,
Tregs are generated when CD4+ T-cells recognize an MHC-II bound antigen in the context
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of immunosuppressive cytokine8. Unlike T-helper cells, Tregs dampen the immune
response and play an important role in immune homeostasis and tumour immune evasion11.
Conversely, CD8+ T-cells have the potential to differentiate into cells with cytotoxic
capacity to eliminate virally infected and tumour cells: these T-cells have been termed “the
foot soldiers of the immune system”12. CD8+ T-cells differ from CD4+ T-cells in that they
recognize foreign peptides presented onto MHC-I molecules, which are found on all
nucleated cells12. Peptides presented onto MHC-I molecules allow CD8+ T-cells to
recognize these cells as non-self10. CD8+ T-cells have an anti-tumour function and exert
cell-mediated cytotoxicity to kill cancer cells12. T-cells, in general, play an essential role in
anti-tumour immunity, as increased T-cell infiltration (both CD4+ and CD8+ T-cells) is
often associated with improved prognosis of cancer patients 7. The focus of this thesis will
be on stimulating a T-cell response, mainly CD8+ T-cells, in tumours that are typically
devoid of T-cells.

In order to understand the manner in which T-cells are primed and trafficked into tumours,
an overall understanding of the “Cancer-Immunity Cycle” is essential. This cycle begins
with the release of tumour antigens, which are engulfed and processed by antigenpresenting cells, more specifically dendritic cells (DCs)13. DCs make their way through the
lymphatic system and traffic to lymphoid organs. In the lymphoid organs, DCs, with their
respective antigens loaded onto surface MHC-I or MHC-II molecules, will present peptides
to CD8+ or CD4+ T-cells, respectively14. Importantly, the process in which DCs internalize
and present endogenous antigens from tumours cells that do not directly infect DCs is called
cross presentation15. Cross presentation is critical in generating an immune response against
tumour cells15. Following the presentation of tumour antigens onto MHCI molecules, Tcells with a TCR that recognizes their respective antigen results in the priming of naïve Tcells15. Fully activated CD8+ T-cells then traffic to the tumour where they recognize MHCI bound tumour antigens on the surface of tumour cells and target them for destruction 14.
This tumour cell killing results in the release of other tumour antigens including
neoantigens (true foreign antigens) and the cancer immunity cycle continues14. Cancer cells
are often able to disrupt this cycle through different mechanisms and overcome anti-tumour
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immunity. An important example of such a disruption is the expression by tumour cells of
ligands for immune checkpoint molecules present on T-cells, which dampen the antitumour functions of T-cells7. Thus, immune checkpoint inhibitors (ICIs) are important as
they allow for the reinvigoration of T-cells and, consequently, restoration of the cancer
immunity cycle7. Despite the promise of ICIs, many cancers do not respond to these drugs.
Thus, studying ICI-refractory tumour cells and discovering a novel mechanism to sensitize
these tumours to ICIs can serve as an important way to trigger anti-tumour immunity.
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1.2 – Immunotherapy with immune checkpoint inhibitors
1.2.1 Immune checkpoint inhibitors
Immune checkpoints are molecules expressed on T-cells that negatively regulate activation
or effector functions of these cells 16. The evolutionary purpose of immune checkpoints is
to prevent a harmful overactivation of the immune system and to maintain immune
homeostasis16. However, cancer cells exploit immune checkpoints to dampen anti-tumour
immune responses17. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that
bind to these regulatory proteins and hinder the immune dampening effects of immune
checkpoints17. Two major immune checkpoints studied in the context of cancer are
“cytotoxic T-lymphocyte-associated protein 4” (CTLA-4) and “programmed cell death
protein 1” (PD-1) and its ligand PD-L1. PD-1 will be the main focus of this thesis; however,
it is important to understand the differences between these two immune checkpoints and
their distinct role in dampening the immune response.
CTLA-4 is an immune checkpoint that plays a role in early T-cell activation stage18. CTLA4 is expressed on T-cells upon binding of T-cell receptor (TCR) to an antigen MHC
complex on antigen-presenting cells. CTLA-4 competes with CD28 (a costimulatory
molecule expressed on T-cells) in binding to CD80 (B7-1) and CD86 (B7-2) ligands
expressed on antigen-presenting cells18. CD28 binding to CD80 and CD86 is required for
proper T-cell activation as it provides a co-stimulatory signal for effective T-cell
activation18. CTLA-4 binds to CD80 and CD86 with a higher affinity and often
outcompetes CD28, which prevents T-cell activation and instead induces T-cell anergy18.
Moreover, as T-cells become activated, CTLA-4 is trafficked from intracellular vesicles,
where it is stored in T-cells, to the cell surface to prevent overactivation of T-cells17. AntiCTLA-4 antibodies were first tested, in preclinical models, as a treatment against tumours
by James Allison and his group19. Their study remarkably showed that CTLA-4 blockade
in vivo enhanced immune-related anti-tumour responses with durable efficacy19. Since
then, anti-CTLA-4 has been used to treat melanoma patients. These patients have a very
high TMB due to the ultraviolet (UV) DNA damage induced nature of the cancer 20. In
randomized controlled trials, 22% of melanoma patients showed sustained long-term (>3
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years) benefits in response to ipilimumab, an anti-CTLA-4 ICI18. CTLA-4 is mainly
expressed on CD4+ T-cells, therefore ipilimumab primarily activates CD4+ T-cells21. It is
important to note that this drug can also have some serious side effects related to the
activation of the immune system against self-antigens22. These can include skin rashes,
colitis and endocrinopathies22.

PD-1, another immune checkpoint molecule, inhibits T-cell effector functions including
cytokine secretion and cytotoxicity18. PD-1-mediated immune regulation most often
involves T-cells that have been activated before and occurs in peripheral tissues rather than
lymph nodes18. T-cells express PD-1 after activation, as a mechanism to prevent
overactivation of the immune system18. PD-1 binds to its ligands, PD-L1 and PD-L2, which
are often found on antigen-presenting cells, myeloid cells, and tumour cells 23. The PD1/PD-L1 interaction hinders T-cell activation and proliferation18. Tumour cells take
advantage of this axis of inhibition in order to downregulate the T-cell’s cytotoxic capacity
and induce a state of T-cell exhaustion18. Monoclonal antibodies that target either PD-1, or
PD-L1, in order to block this ligand receptor interaction, can re-invigorate T-cells24. More
specifically, these monoclonal antibodies reinvigorate cytotoxic CD8+ T-cells and they can
then go on to target and kill cancer cells24.

T-cells express a number of other co-inhibitory receptors that play an important role in
regulating the T-cell immune response25. These immune checkpoints include lymphocyteactivation gene 3 (LAG-3), T-cell immunoglobulin mucin domain-3 (TIM-3) and T-cell
immunoreceptor with Ig and ITIM domains (TIGIT)26. LAG-3 is expressed on activated
CD8+ and CD4+ T-cells and binds to a number of molecules including MHCII, (with higher
affinity than CD4), LSECtin and galectin3 (found on tumour cells)25. When LAG-3 binds
to these molecules, it negatively regulates T-cell signalling and results in reduced T-cell
proliferation and cytokine production25. TIM-3, another immune checkpoint, binds to
galectin9 found on various tumour cells25. Binding of TIM-3 and galectin9 results in the
phosphorylation of tyrosine residues on the TIM-3 tail and stimulates downstream
inhibitory signals that negatively regulate the T-cell response25. Interestingly, the coinhibitory receptor TIGIT was discovered through bioinformatic analysis 25. TIGIT binds
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CD155 and through its immunoreceptor tyrosine inhibitory domains, TIGIT inhibits T-cell
proliferation and dampens the overall T-cell effector capacity25.
1.2.2 Predictors of response to anti-PD1 therapy
Clinical success of anti-PD1 therapy depends on a number of factors, including PD-L1
expression on tumour cells. For example, patients with tumours expressing higher levels of
PD-L1 respond better to ICI therapy18. Higher somatic mutation frequency in tumours is
also associated with better overall response rates to anti-PD1 treatment20. The heightened
response in patients with high TMB tumours is thought to occur due to the increase in
neoantigens resulting from somatic mutations. Neoantigens are “new antigens” that have
not been otherwise recognized as “self” by T-cells during thymic development, therefore,
they are considered true foreign antigens by the immune system10. Neoantigens render
tumours more immunogenic, allowing cytotoxic T-cells to recognize them as non-self and
target them for destruction20. Microsatellite instable (MSI) tumours have some of the
highest somatic mutation frequencies and also display heightened overall responses to
ICIs20. Interestingly, pembrolizumab, which targets PD-1, was the first ICI that was FDA
approved on a molecular biomarker basis and is used for all microsatellite instability-high
(MSI-h) and mismatch repair-deficient (MMR-d) cancers. This underscores the importance
of microsatellite instability for favorable ICI response20. A growing shift in ICI research
has moved towards studying factors, such as the ones listed above, that influence T-cell
infiltration into tumours and promote ICI response27.
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1.3 - Tumour microenvironment and immune checkpoint
inhibitors
1.3.1 Immunogenic tumour microenvironment
The immunogenicity of tumours can have a substantial impact on prognosis of cancer
patients and success of their response to immunotherapies such as ICIs28. Highly
immunogenic tumours, termed “hot tumours”, refer to a T-cell-inflamed tumour
microenvironment (TME)28. Hot tumours are highly infiltrated with T-cells and show signs
of immune activation28. However, cold tumours are characterized as having a TME where
T-cells are excluded28. The presence of cytotoxic T-lymphocytes in the TME demonstrates
that the adaptive immune system recognizes the cancer as foreign and is able to infiltrate
the tumour. However, in order for a tumour to be considered as highly immunogenic or
“hot”, it not only has to be infiltrated with T-cells, but it also has to be inflamed. Within
infiltrated-inflamed tumours, cytotoxic lymphocytes express high levels of effector
molecules such as interferon gamma (IFN) and granzyme B27. The presence of these
activation markers indicates that cytotoxic T-lymphocytes in the tumour are not simply
bystanders but are able to recognize cancer cells as foreign and elicit an immune response27.
1.3.2 Tumour mutational burden and TME
High tumour mutational burden (TMB) of tumours correlates with tumour
immunogenicity27. A high TMB may seem paradoxical, as mutations acquired by cancer
cells are what allow them to gain the ability to proliferate uncontrollably and escape cell
death10. However, a higher number of mutations within the tumour can lead to more
neoantigens that can be recognized by the immune system as foreign10. Moreover, a high
TMB is associated with higher immune cell infiltration10. As these tumours acquire more
mutations, they are able to present more foreign peptides on their MHC-I molecules that
can then be recognized as foreign by the cytotoxic T-cells that infiltrate the tumour29.
Immune cell infiltration, along with high levels of foreign peptides in high TMB tumours,
is likely responsible for their enhanced ICI response29. ICIs often show efficacy in such
patients, because as immune cells become exhausted in this highly immunogenic TME,
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ICIs rescue them from their exhausted state, and they become re-invigorated to recognize
and kill tumour cells in an antigen specific manner10.

9

Figure 1.1. DNA MMR-deficiency in tumours results in heightened tumour
immunogenicity.
Immunologically hot tumours are characterized by an increase in T-cell infiltration and
immune recognition. Such tumours respond favorably to ICIs because of their pre-existing
anti-tumour immunity. Recently, mismatch repair deficient patients have been shown to
respond well to ICIs and have a TME that has been characterized as immunologically hot
and conducive to ICI response. These immunologically hot tumours have genomic
instability, which leads to many genomic mutations. When such mutations occur in coding
regions of the genome, leading to new potentially antigenic peptides (neopeptides) being
produced. These neopeptides can then be presented by MHC-I molecules and tumours are
subsequently recognized as non-self by the immune system. This recognition of the tumour
as foreign results in the infiltration of cytotoxic T-cells into the tumour and the release of
pro-inflammatory cytokines and cytolytic enzymes to target and kill cancer cells. However,
the immune system has evolved mechanisms to prevent the overactivation of the immune
system and it therefore dampens the T-cell response. As such, these cytotoxic T-cells
express activation and exhaustion immune checkpoint molecules such as PD-1, TIM-3,
LAG-3 and TIGIT, which hinder the T-cell response against tumours. Notably, this preexisting T-cell infiltration and immune checkpoint expression results in a favorable
response of MMR-deficient patients when compared to patients with genomically stable
cold tumours. Genomically stable tumours such as neuroblastoma tumours often lack a preexisting anti-tumour response, and therefore show little benefit to ICIs.
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1.4 – Hot tumours and microsatellite instability
The tumour mutational burden (TMB) is a strong biomarker for immunogenicity as
previously discussed. A major example of highly immunogenic cancers with a high TMB
signature is a subset of colorectal adenocarcinoma (COAD READ) patients with highly
microsatellite instable (MSI-h) or DNA mismatch repair-deficient tumours27. As a result of
this TMB signature, these patients respond favorably to immune checkpoint inhibitors
(ICIs). It is important to note that deficiencies in other types of DNA repair mechanisms
may also result in a high TMB and favorable response to ICIs. However, the focus of this
thesis will be on the DNA-MMR pathway, as tumours with a DNA-MMR deficiency have
been clinically shown to respond to ICIs across a number of cancers.
1.4.1 DNA mismatch repair pathway and microsatellite instability
Microsatellites are repetitive DNA sequences that range from 1 to 6 nucleotides in length 30.
These repetitive sequences are error prone during DNA replication as slippage between the
primer and template strand occurs. This slippage results in an insertion deletion loop that
can then be recognized and repaired by the DNA-MMR machinery31. However, when
DNA-MMR is impaired, these mutations are not corrected, and the result is microsatellite
instability. Four important genes in the DNA mismatch repair complex are the mutL
homologue (MLH1), mutS homologue (MSH2), mutS homologue 6 (MSH6) and postmeiotic segregation increase 2 (PMS2)32. When a mismatch occurs, MSH2 binds to MSH6
forming the mutS homologue and MLH1 associates with PMS2 forming the mutL
homologue32. The mutS and mutL guide mismatch recognition and recruit exonuclease 1
to remove mismatching nucleotides32. Polymerase δ fills in the gap created by the
exonuclease and DNA ligase repairs the phospho-diester backbone32. Importantly,
mutation or silencing of any one of the four genes responsible for mismatch recognition
can result in microsatellite instability (MSI or MSI-high)32. However, in MSI-h COAD
READ patients, the most common cause of MMR deficiency is the hypermethylation of
the MLH1 promoter, leading to loss of gene expression29.
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Figure 1.2. DNA mismatch repair pathway

*Adapted from: Alexinna MN et al. Nature 2015
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1.4.2 DNA mismatch repair pathway and tumour immunogenicity
Tumours that are DNA-MMR-deficient (dMMR) acquire more mutations in comparison to
DNA-MMR-proficient tumours (pMMR) (>12 mutations/106 DNA bases vs <8.24
mutations/106 DNA bases, respectively)29. This high mutation load results in more new
peptides generated by the tumours and presented onto their MHC I molecule29. As such,
MMR deficiency renders tumours more immunogenic as these tumours become highly
infiltrated and inflamed27. More specifically, these tumours have a large number of
cytotoxic T-lymphocytes that express markers of activation, such as PD-127. These tumours
also express higher levels of type I IFN genes, which aids in triggering anti-tumour
immunity, when compared to their mismatch repair-proficient counterparts.29 As such,
MSI-h COAD READ tumours are considered “hot tumours” and these patients have a better
prognosis when compared to microsatellite stable (MSS) COAD READ patients32.
Additionally, due to their highly immune inflamed TME, dMMR MSI-h patients respond
better to ICIs29.
1.4.3 Inducing MMR-deficiency in poorly immunogenic tumours: turning “cold”
tumours “hot”
MMR-deficient tumours have been characterized as immunologically hot, with higher
immune cell infiltration and by definition, these tumours illicit a stronger immune
response when compared to cold tumours27. A number of scientists have therefore studied
the effect of inducing MMR-deficiency on immunologically cold tumours in order to
render these tumours more immunogenic. Germano et al. showed that inducing MMRdeficiency in the immunologically cold pancreatic tumour resulted in a heightened antitumour response against these tumours when compared to their MMR proficient counter
parts33. Mandal et al. similarly showed that inducing MMR-deficiency in a murine
colorectal cell line resulted in an enhanced immune dependent anti-tumour response in
mice34. Interestingly, both groups also showed that inducing MMR-deficiency resulted in
higher tumour immunogenicity, which sensitized these immunologically cold, ICI
refractory tumours, to this treatment33,34. Unfortunately, this concept of inducing MMRdeficiency in cold tumours has not been well studied in childhood cancers, which are an
important subset of tumours that do not respond to ICI treatment. Cancers, such as
13

neuroblastoma, accounts for disproportionate mortality among childhood cancers35.
Neuroblastoma tumours are immunologically cold and do not illicit a strong anti-tumour
response and consequently do not benefit from ICI treatment35.
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1.5 – Neuroblastoma: “cold tumours” and immunotherapy
In the previous section, hot tumours and their heightened response to immunotherapy were
discussed. Conversely, “cold tumours” are characterized as non-immune-inflamed tumours
largely devoid of immune cells28. One example of such a tumour is neuroblastoma, which
is the most common extra-cranial solid tumour diagnosed in children35. Patients diagnosed
after 18 months of age often display metastatic or unresectable disease and have a very
poor prognosis (40-50%)35. Neuroblastoma is largely non-immunogenic. These tumours
have a low TMB, which prevents the body from mounting an effective immune response
against the tumour.

Immunotherapy with ICIs largely relies on the re-invigoration of a pre-existing immune
response to restore effective immune targeting of cancer cells. However, in the case of
neuroblastoma, tumour antigen availability is very limited, preventing such an immune
response against the tumour36. Neuroblastoma cells are therefore largely invisible to
cytotoxic T-cells limiting T-cell infiltration into tumours. Neuroblastoma cells also express
negatively charged carbohydrate epitopes on their surface that are not only nonimmunogenic, but also immunosuppressive36. Additionally, these tumours release
immunosuppressive molecules such as FAS ligand into the TME, further rendering the
microenvironment tumour-suppressive36. Pro-tumourigenic immune cells are also recruited
to the TME, such as anti-inflammatory macrophages that promote tumour growth and
inhibit anti-tumour natural killer (NK) cells36. Some studies have also shown that the
immune-suppressive populations, such as myeloid derived suppressor cells (MDSCs) and
Treg cells, play a role in creating an immunosuppressive tumour microenvironment36.

This highly immunosuppressive tumour microenvironment along with the limited epitope
landscape renders these tumours immunologically cold36. Immunologically cold tumours
cannot induce a proper immune response and are devoid of cytotoxic T-lymphocytes
needed for a successful response to ICIs.
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1.6 Rationale, hypothesis and aims
Rationale
Patients with DNA-MMR repair deficiencies have highly immune infiltrated and inflamed
tumours27. This phenotype is thought to arise due to the increase in somatic mutations in
these tumours, ultimately producing more neopeptides that can stimulate an immune
response27. Moreover, because of this highly infiltrated and immune-inflamed phenotype,
patients with DNA-MMR deficiencies respond well to immune checkpoint inhibitors20.
Therefore, I hypothesize that impairing DNA-MMR machinery in an otherwise stable and
non-immunogenic cancer, neuroblastoma, would stimulate an anti-tumour immune
response. Furthermore, I propose that this activation of the immune system can, in turn,
sensitize these tumours to immune checkpoint inhibitors.
Hypothesis
Induction of DNA-MMR deficiency in an immunologically cold tumour will result in
increased tumour immunogenicity with a heightened anti-tumour response in immunecompetent mice. This induction will also produce a robust anti-tumour response
characterized by phenotypic changes in tumour infiltrating lymphocytes (TILs).
Aims
Aim 1: Induce MMR deficiency in the neuro-2a neuroblastoma cell line (representing a
low TMB cancer).
Aim 2: Study the effect of inducing MMR-deficiency on neuro-2a cells.
Aim 3: Analyze anti-tumour response of mice bearing MMR-deficient (dMMR) and MMRproficient (pMMR) tumours and treated with ICIs.
Aim 4: Compare the immune phenotype of TILs from dMMR and pMMR tumour-bearingmice using multicolour flow cytometry.
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Chapter 2
Methods
2.1 – Cell culture
The murine neuroblastoma cell line, neuro-2a, was obtained from the American Type
Culture Collection (ATCC) and was used for the experiments described below. These cells
were grown in culture at 37 degrees Celsius, 5% CO2. Cells were cultured in RPMI140
media (Wisent Bio Products, Saint-Jean Baptise, QC) supplemented with 10% fetal bovine
serum (ThermoFisher Scientific, Waltham, MA, USA). For the majority of the
experiments, cells were expanded to a ~70-80% confluency. In order to detach cells from
cell culture plates/flasks, media was removed, and plates/flasks were washed with PBS
(Wisent Bio Products, Saint-Jean Baptise, QC, CA) to remove any residual FBS. Trypsin
(Wisent Bio Products, Saint-Jean Baptise, QC, CA) was added (0.5-1.5ml) to detach cells
from the surface of plates and these were placed in an incubator at 37 degrees Celsius, 5%
CO2 for ~3 minutes. Once cells were visibly detached, 10ml of RPMI media (Wisent Bio
Products) supplemented with FBS (ThermoFisher Scientific) was added to the trypsin-cell
mixture. Harvested cells were then processed following the methods described below.
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2.2 – CRISPR Cas9 MLH1 KO Plasmid

Figure 2.1 CRISPR Cas9 MLH1 KO Plasmid
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and the CRISPRassociated protein (Cas9) are used to degrade target genetic material in order to knock-out
a gene of interest. I used the MLH1 CRISPR Cas9 KO Plasmid from Santa Cruz
Biotechnology in order to knock-out the MLH1 gene in the murine neuroblastoma (neuro2a) cell line. This CRISPR Cas9 plasmid consists of a pool of 3 different plasmids with
distinct target-specific guide RNAs, a GFP encoding region and a Cas9 encoding region.
A pool of 3 plasmids targeting different portions of the MLH1 gene, was used in order to
maximize knock-out efficiency. Other important regions of the plasmids are indicated in
the

figure

above

obtained

from

the

Santa

Cruz

Biotechnology

website

(https://www.scbt.com/p/mlh1-crispr-knockout-and-activation-products-m).
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2.3 - CRISPR Cas9 transfection
MLH1 CRISPR CAS9 KO plasmid was purchased from Santa Cruz Biotechnology (Santa
Cruz Biotechnology, Dallas, TX, USA). In a 6-well plate, 50 000 neuro-2a neuroblastoma
cells were seeded in 3 ml of RPMI 140 (Wisent Bio Products, Saint-Jean Baptise, QC)
supplemented with 10% FBS (ThermoFisher Scientific) and grown to 80% confluency.
After 24 hours, 1ug of plasmid DNA (Santa Cruz Biotechnology) was mixed with 3ml of
lipofectamine 3000 (ThermoFisher Scientific, Waltham, MA, USA) and 500ul of medium.
Cells were incubated for 24 hours. Successful plasmid transfection was visualized using
fluorescence activated cell sorting (FACS) for green fluorescence protein (GFP)
fluorescence. GFP+ cells were sorted, 1 cell per well in a 96-well plate. Cells were grown
until a colony was formed and were then trypsinized (Wisent Bio Products) and transferred
onto a 24-well plate. They were further expanded and finally transferred onto a T25 plate.

2.4 – Western blot
Selection of successful MLH1 KO clones was confirmed by western blot. Wild type neuro2a cells and neuro-2a cells transfected with the MLH1CRISPR Cas9 KO plasmid, were
grown in vitro. Protein was collected from neuro-2a cells using 100 μl of RIPA (name
derived from its original intended application, radio-immunoprecipitation assay) lysis
buffer with protease inhibitors (ThermoFisher Scientific, Waltham, MA, USA), which
lyses and extracts protein from mammalian cells. A cell scraper was then used, and the
lysate was transferred to a 15 ml tube and left on ice for ~15 minutes. Cells were sonicated
twice, 2 seconds each time, and again left on ice for 15 minutes. Cells were centrifuged at
13000g for 5 minutes at 4 degrees Celsius. The concentration of protein from the sample
was measured using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, USA) and reading
through the spectrophotometer. Samples were then reduced and denatured (105 degrees
Celsius) and Sodium Dodecyl Sulfate (SDS) sample buffer with -mercaptoethanol were
added to the protein sample. SDS is a detergent that denature proteins and gives them all
an overall negative charge in order for the proteins to separate based off of size. Cell lysates
(30 μg) were loaded into every well of the 10% SDS-PAGE gel and run at 120V for ~1

19

hour in a Bio-Rad electrophoresis apparatus (Bio-Rad, Hercules, CA, USA) with running
buffer (28.8g of glycine, 6.04g of Tris base, 2 ml of 10% SDS). Protein samples that had
then separated were then transferred onto a membrane using transfer buffer (25mM Tris,
192 mM glycine at a pH of 8.3 with 20% methanol). Transfer to membrane was carried out
within a cassette with filter paper and fiber pads and was run at 30V overnight. After
proteins were transferred onto the membrane, the membrane was submerged in 2 ml of 5%
skim milk (prepared from powder) for 1 hour on a shaker. Primary anti-MLH1 antibodies
at a 1:2000 (Abcam, Cambridge, UK) concentration were then added to the membrane for
~2 hours on a shaker at room temperature (RT). This was then washed with TBST for 5
minutes, 3 times. Finally, HRP-conjugated secondary anti-rabbit antibody at a 1:2000
(Millipore Sigma, Burlington, MA, USA) concentration was added to the membrane. HRP
chemiluminescent substrate, luminate forte (Millipore Sigma, Burlington, MA, USA), was
thinly layered onto the membrane and this was then imaged.

2.5 – Proliferation assay
Neuro-2a clones 12 (pMMR cell line) and clone 4 (dMMR cell line) were grown for 7
weeks in vitro, passaged ~3 times per week, to allow for mutations to accumulate. In order
to ensure that neuro-2a cells with the MLH1 KO (dMMR) and that neuro-2a cells still
expressing MLH1 (pMMR) were growing at similar rate in vitro, a proliferation assay was
conducted. Neuro-2a cells were thawed and then given a day to adhere to the T75 flasks.
The following day, cells were trypsinized (Wisent Bio Products) and spun down at 300g
for 6 minutes at 4 degrees Celsius. Cells were then washed twice with PBS (Wisent Bio
Products) and spun down at 300g for 6 minutes at 4 degrees Celsius. Cells were counted
using the Beckman Coulter cell counter (Beckman Coulter, Brea, CA, USA) and they were
then spun down at 300g for 6 minutes at 4 degrees Celsius. Neuro-2a cells were then diluted
for a final concentration of 50,000 cells per 100 ul and 100 ul was added to a T25 flask
with 10 ml of RPMI media (Wisent Bio Products) with 10% FBS (ThermoFisher
Scientific). There was a total of 6 flasks with pMMR neuro-2a cells and 6 flasks with
dMMR neuro-2a cells. Cells were placed in an incubator at 30 degrees Celsius, 5% CO2 to
grow. The next day, 3 flasks with pMMR neuro-2a cells and 3 flasks with dMMR neuro2a cells were removed from the incubator to calculate the number of cells that adhered onto
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the flasks and establish the baseline number of cells for each clone. Cells were left to grow
for an additional 4 days. At day 4, the rest of the flasks with pMMR and dMMR neuro-2a
cells were counted using the Beckman Coulter cell counter (Beckman Coulter). This cell
count represents the total number of cells after a 4-day growth period. The proliferation
rate was calculated by simply dividing the number of cells at day 4 by the initial number of
cells that adhered onto the flasks to obtain the fold increase of cell growth.

2.6 – Mice
A/J mice were purchased from the Jackson Laboratory (Jackson Laboratory, Bar Habor,
ME, USA) and immunodeficient SHO mice were purchased from Charles river (Charles
river, Wilmington, MA, USA). Mice were 6-8 weeks of age when acquired and were all
female. These mice were housed at the Victoria Research Lab Vivarium. Protocols
involving animals were approved by the Animal Care Committee (ACC) at Western
University.

2.7 – Tumour implantation, immune checkpoint inhibitor
treatment, tumour measurement and blood collection.
2.7.1 – Immune checkpoint inhibitor experiments
For the in vivo experiments, 5x105 pMMR and dMMR neuro-2a cells were injected
subcutaneously into the right flank of mice (day 0). Tumours were palpable ~10 days post
tumour injection. Therefore, at day 7 or 10 depending on the experiment, mice were given
250 ug of anti-PD1 antibody in 100 ul of PBS injected intraperitoneally (i.p.) every 3 days
for a total of 3 injections on days 10, 13, and 16. Tumour volumes were measured using
callipers, and calculated by measuring their length and width, and recorded in mm3. When
the first tumour volumes reached ~1400mm3, all mice were euthanized.
2.7.2 – Tumour growth in immunodeficient mice experiments
When analyzing tumour growth in vivo in immunodeficient animals, 500 000 pMMR
neuro-2a cells (C12) and dMMR neuro-2a cells (C4) were injected subcutaneously into the
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right flank of mice (day 0). Tumour volumes were measured at days 7, 10, 13, 16, 20, 24.
Mice were sacrificed individually when their tumour volumes reached ~1400 mm3.
2.7.3 – Blood collection
Blood was collected at 2 time points from A/J mice. The first time point was at day 7, the
“before treatment time point”. The second time point was at day 14 and this was the “after
treatment time point”. For blood collection, blood was collected from the saphenous vein
on the right leg of mice. The blood was then left to settle at RT for 30 minutes. After 30
minutes, blood was centrifuged at 15000 RPM at room temperature and the supernatant
was collected and frozen at -80 degrees Celsius.

2.8 – Isolation of splenocytes, lymph nodes and TILs from
mice
2.8.1 – Isolation of splenocytes and lymph nodes from mice
Mice were euthanized by being placed in a chamber with carbon monoxide for 30 seconds.
Spleens were removed and placed in ice-cold RPMI media (Wisent Bio Products) and kept
on ice. The spleen was placed in a 70um strainer (ThermoFisher Scientific, Waltham, MA,
USA) and the plunger end of a sterile syringe was used to homogenize the spleen into a
well of a 6-well plate with RPMI media (Wisent Bio Products). Media was then transferred
from the plate to a 15 ml tube and placed on ice. To acquire a single cell suspension, the
cell suspension was then centrifuged at 300 g for 8 minutes at 4 degrees Celsius. The cell
pellet was broken up with 1 ml of PBS (Wisent Bio Products) and then 13 ml of PBS were
added to wash cells. Tube was transferred to the centrifuge for the wash at 300 g for 8
minutes at 4 degrees Celsius. This wash was repeated one more time. One ml of red blood
cell (RBC) lysis (NH4Cl (ammonium chloride) 8.02gm NaHCO3 (sodium bicarbonate)
0.84gm EDTA (disodium) 0.37gm)) buffer was added to break up the pellet and 2 more ml
of buffer were added and the tube was placed on ice for 3 minutes (mixing suspension every
30 seconds). Ten ml of RPMI media (Wisent Bio Products) was subsequently added and
the tube was centrifuged at 300 g for 8 minutes at 4 degrees Celsius. Pellet was once again
broken up with 1 ml of PBS (Wisent Bio Products) and 13 ml of PBS was added to wash
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the cells. PBS (Wisent Bio Products) was added for a final wash, and 500 ul was removed
prior to centrifugation to obtain a cell count using the Beckman Coulter (Beckman Coulter)
cell counter. After the final wash, the pellet was broken up with 1 ml of PBS (Wisent Bio
Products) and additional PBS was added as needed to have ~1 million cells/ml. 250 ul of
this suspension (250,000 cells) was then transferred to a well on a 96-well plate for further
antibody staining.
2.8.2 – Isolation of tumour infiltrating lymphocytes (TILs) from mice
Mice were sacrificed by being exposed to carbon monoxide in an enclosed chamber for 30
seconds. Dead animals were then removed, and the tumour was extracted and placed in
RPMI (Wisent Bio Products) media on ice. Tumour was cut into small 2-4mm pieces and
placed in a 50 ml tube with RPMI media (Wisent Bio Products) using the Miltenyi Biotec
Tumour Dissociation Kit (Miltenyi Biotec, Bergisch, GL, DE). The tumour sample was
homogenized using the GentleMacs Dissociator (Miltenyi Biotec, Bergisch, GL, DE), on
the “tumour mouse sample 03” setting, for solid tumour homogenization. Tubes were then
rested on a rotator, which was placed in an incubator (37 degrees Celsius) for 40 minutes.
Samples were removed and run through a 70um strainer (ThermoFisher Scientific) and then
centrifuged at 300 g for 8 minutes at 4 degrees Celsius. Cell pellet was broken up with 1 ml
of PBS (Wisent Bio Products) and then 30 ml of PBS was added to wash the pellet.
Suspension was centrifuged at 300 g for 8 minutes at 4 degrees Celsius. This washing step
was repeated. One ml of RBC lysis buffer was added to break up the pellet and 4 more ml
of the lysis buffer was added, and the tube was placed on ice for 5 minutes (mixing
suspension every 30 seconds). Thirty ml of RPMI media (Wisent Bio Products) were then
added and the tube was centrifuged at 300 g for 8 minutes at 4 degrees Celsius. Pellet was
once again broken up with 1 ml of PBS and 30 ml of PBS (Wisent Bio Products) were
added to wash the cells. PBS (Wisent Bio Products) was added for a final wash, and prior
to centrifugation, 500 ul of the mixture was removed to count the number of cells using the
Beckman Coulter Cell counter (Beckman Coulter). After the final wash, the pellet was
broken up with 1 ml of PBS (Wisent Bio Products)

and additional PBS was added as

needed to have ~5 million cells/ml. 200 ul of this suspension (1 million cells) was then
transferred to a well on a 96-well plate for further antibody staining.
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2.9 – Flow cytometry
Flow cytometry was required for experiments involving neuro-2a cells (grown in vitro),
splenocytes, lymph node cells, and tumour cells extracted from mice post-euthanasia. All
cells were seeded in a 96-well plate with 200,000 – 1x106 cells per well suspended in 250
ul of PBS. Cells were spun down at 3000g for 6 minutes at 4 degrees Celsius. Supernatant
was removed and cells were suspended in a live/dead zombie dye (Biolegend, San Diego,
CA, USA) for 15 minutes at RT in the dark. Cells were washed with FACS buffer (1x PBS
with 5% FBS) and spun down at 1800 g for 6 minutes at 4 degrees Celsius. Supernatant
was then removed and 20 ul of Fc Block (Biolegend, San Diego, CA, USA) with a
concentration of 10 ug/ml was added to each well and left for 15 minutes at RT in the dark.
Mixes of antibodies were then added to the wells and left for 30 minutes on ice without
removing the Fc block. Cells were washed with the FACS buffer (PBS with 5% FBS) and
centrifuged at 3000g for 6 minutes at 4 degrees Celsius, twice. In order to fix cells, fixation
buffer (Biolegend, San Diego, CA, USA) was diluted 1:2 with deionized water and 50 ul
of the diluted fixation buffer was added to each well and left for 20 minutes at RT. Cells
were washed twice with FACS buffer. Supernatant was removed and cells were transferred
from each well in 100 ul of FACS buffer to a polystyrene tube with 300 ul of FACS buffer.
Tubes were placed in the refrigerator (4 degrees Celsius) in the dark and run the next day
on the BD LSRII Cytometer.
Table 1. Antibodies and reagents table
Antibody

Fluorophore

Clone

Source

CD3

Brilliant Violet 711

17A2

BioLegend

CD4

Alexa Fluor 700

GK1.5

BioLegend

CD8a

PerCP/Cyanine5.5

53-6.7

BioLegend

PD1

PE/Dazzle 594

29F.1A12

BioLegend

LAG3

PE/Cyanine 7

C9B7W

BioLegend

TIM3

PE

B8.2C12

BioLegend
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TIGIT

APC

IG9

BioLegend

CD39

Alexa Fluor 647

Duha59

BioLegend

CD107a

Brilliant Violet 421

1D4B

BioLegend

CD38

Alexa Fluor 488

90

BioLegend

CD25

Brilliant Violet 605

PC61

BioLegend

CD152

Brilliant Violet 605

UC10-4B9

BioLegend

2.10 – TCGA data mining
The Cancer Genome Atlas database was bioinformatically mined to extract data from the
colorectal adenocarcinoma (COAD READ) dataset. mRNA sequencing data was obtained
from the Broad Genome Data Analysis Firehose database (https://gdac.broadinstitute.org/).
This dataset was level 3 RSEM (RNA-Seq by Expectation Maximization) normalized
illumina high throughput sequencing data. The normalized RNA seq data file name is
“illuminahiseq_rnaseqv2-RSEM_genes_normalized (MD5)”

and

was

subsequently

converted into a CSV file format. The COAD READ cohort has 631 total samples. Using
Python libraries (csv, os and itertools), 3 excel files were created with patient ID
information for each sample along with RNAseq values for a number of genes. Samples
were divided into the 3 excel files according to whether they were classified as “normal”,
“MSS” or “MSI-h” in the clinical file titled “Merge_Clinical (MD5)” on the Firehose
database website (https://gdac.broadinstitute.org/). COAD READ patient samples with
both microsatellite status information along with gene expression data were therefore
grouped into normal (n=51), MSS (n=257) and MSI-h (n=51) primary tumour tissue
samples. Metastatic samples were not included in the analysis. Using the python library
Seaborn, box plots were generated in order to compare gene expression between groups.
The center line of boxplots represents the media and the upper and lower limits indicate the
75th and 25th percentiles respectively. Mann-Whitney U test was used to statistically
compare the groups. In order to generate the overall survival graphs, I analyzed gene
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expression as described above. Moreover, I stratified patients according to their gene
expression into “high” and “low” groups and used the lifelines library to generate the
overall survival plots. The 2-sided log-rank test was used to compare the overall survival
in patients highly expressing a gene and patients expressing the gene to a lower extent.

2.11 – Statistical analysis
In vitro data are represented as mean ± standard deviation (SD). Results were analyzed
using Student’s t-two-tailed unpaired t test. Moreover, in vivo experiments requiring the
comparison between more than 2 groups statistical analysis was performed using the oneway ANOVA test. These results are represented as mean ± standard deviation (SD).
Finally, for the survival experiments statistical analysis was performed using the two-sided
log-rank (Mantel-Cox) test. For all tests, a p value < 0.05 (indicated by an asterisk [*] in
graphed data) was chosen a priori as an indication that the null hypothesis could be rejected.
However, data showing differences at more stringent bars of significance (** p ≤ 0.01, ***
p ≤ 0.001, **** p ≤ 0.0001) are also shown as matter of interest only: where significance
is ascribed, only p<0.05 was considered. Where p values were greater than 0.05, “ns”
indicates “not significant”.
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Chapter 3
Results
3.1 Colorectal cancer patients with microsatellite
instabilityHIGH tumours express lower levels of the DNA-MMR
repair gene MLH1
DNA-MMR repair genes MLH1, MSH2, MSH6 and PMS2 are essential components of the
DNA-MMR pathway and decreases in expression of these genes is characteristic of a large
number of DNA-mismatch repair deficient (dMMR) tumours. Moreover, MMR-deficiency
often results in microsatellite instability, an event correlated with favourable responses to
ICIs. I therefore set out to determine the levels of 4 major DNA-MMR repair genes: MLH1,
MSH2, MSH6 and PMS2 in the colorectal adenocarcinoma (COAD READ) cohort of The
Cancer Genome Atlas (TCGA) database. I specifically aimed to determine whether these
DNA-MMR genes were significantly downregulated in samples with high microsatellite
instability. I included patients with both microsatellite status information along with RNA
sequencing data. COAD READ primary samples were grouped into 3 major categories:
microsatellite stable (MSS), high microsatellite instabilityhigh (MSI-h) and normal (samples
obtained from normal adjacent tissues from both MSI-h and MSS patients) samples.
Importantly, MLH1 transcript levels were significantly lower in the MSI-h group when
compared to both the MSS and normal tissue groups, whereas MSS samples did not exhibit
any significant differences in their MLH1 transcript levels when compared to the normal
group (Fig.3.1a). Notably, gene expression (mRNA) levels of MSH2 and MSH6 were not
significantly different between MSS and MSI-h subsets (Fig.3.1b, c). Finally, PMS2 levels
were slightly lower in the MSI-h group when compared to the MSS subset: they were,
however, higher than the normal sample group (Fig.3.1d). Together, these results
demonstrate that downregulation of expression of MLH1 DNA-MMR repair genes is a
highly conserved characteristic of highly microsatellite instable primary human colorectal
tumours.
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Figure 3.1. MLH1 is downregulated in microsatellite instable human COAD READ
tumours.
(a) Normalized MLH1, (b) MSH2, (c) MSH6, (d), PMS2 RNA-seq data was obtained
from the TCGA database COAD READ dataset and grouped into normal (n=51), MSS
(n=257) and MSI-h (n=51) tissues. Statistical analysis was performed by non-parametric
Mann-Whitney U test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not
significant).
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3.2 MSI-h tumours are associated with higher numbers of Tcells and levels of pro-inflammatory molecules
MSI-h tumours exhibit a high mutational load, which is often associated with an immuneinflamed phenotype. As such, RNAseq levels of mRNAs for genes that characterize T-cells
(CD3G, CD3D), CD8+ T-cells (CD8a, CD8b), CD4+ T-cells (CD4), pro-inflammatory
cytokine interferon gamma (IFNG) and cytolytic proteins perforin (PRF1) and granzyme
B (GZMB) were analyzed. I found higher transcript levels of T-cell genes (Fig.3.2a)
including those for both CD8+ T-cells (Fig.3.2b) and CD4+ T-cells (Fig.3.2c) in MSI-h
tissues when compared to their microsatellite-stable counterpart. MSI-h tumours also
expressed higher levels of mRNA encoding the pro-inflammatory cytokine IFN (Fig.3.2d)
versus both the MSS and normal samples. Importantly, these highly unstable tumours also
exhibit higher levels of mRNAs for cytolysis-associated genes perforin and granzyme B
(Fig.3.2e) when compared to both the microsatellite-stable and normal tissues. These data
demonstrate that highly unstable MSI-h tumours are both immune infiltrated and inflamed,
unlike MSS tumours which lack this immunogenicity. It is also important to note, that when
I compared the expression of a number of immune genes in either MSS or MSI-h tumour
samples to the expression in normal samples, I observed a decrease in mRNA levels.
Tumours have evolved multiple mechanisms in order to limit immune infiltration and evade
the immune system.37 For example, one of many immune exclusion mechanisms involves
the tumour intrinsic Wnt/beta-catenin pathway.37 This pathway limits T-cell infiltration and
promotes immune suppressive cells.37 Tumour cells can also limit production of effector
chemokines in order to block effector T-cell recruitment into tumours.37 These immune
exclusion mechanisms provide insight into the decrease in immune gene expression
observed in tumour samples when compared to normal samples.
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Figure 3.2. MSI-h tumours express higher levels of T-cells marker and
proinflammatory genes.
Normalized RNA-seq data for T-cell genes (a) CD3G, CD3D, (b) CD8A, CD8B and (c)
CD4 and pro-inflammatory genes (d) IFNg, (e) PRF1 and GZMB were obtained from the
TCGA database COAD READ dataset and grouped into normal, MSS and MSI-h tissues
(n=51, n=257, n=51). Statistical analysis was performed by non-parametric Mann-Whitney
U test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant).
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3.3 Generating an MLH1 knock-out mouse neuroblastoma
cell line
Neuroblastoma is an immunologically cold tumour that is also refractory to immunotherapy
with ICIs35. dMMR tumours, on the other hand, have a high tumour mutational burden and,
as seen in Fig.3.2, are immunologically hot. Rene Figueredo, the lab technician in the
Koropatnick/Maleki lab, transfected the mouse neuroblastoma cell line neuro-2a with an
MLH1 KO plasmid with the goal of generating an immunogenic MMR-deficient neuro-2a
cell line for in vitro and in vivo studies. He then selected multiple clones using FACS
sorting specific for GFP fluorescing cells and then compared MLH1 protein production in
the knock-out clones (C4, C5, C10, C12) to MLH1 produced by the positive control (wild
type neuro-2a cells) (Fig.3.3a). Clone 4 did not produce MLH1 protein, indicated that the
MLH1 gene was successfully knocked-out (Fig.3.3a). This clone was therefore selected as
the dMMR clone and will be referred to as the dMMR cell line for the remainder of this
thesis. Moreover, clone 12 still produced normal levels of MLH1 protein, indicating that
knock-out was unsuccessful (Fig.3.3a). Clone 12 was therefore established as the control
DNA-mismatch repair proficient cell line, along with the parental WT cell line. I will be
referring to clone 12 from this point onward as the pMMR cell line.

Moreover, it was important to ensure that both the dMMR and pMMR cell lines had similar
baseline proliferation rates in vitro before studying their tumour growth in vivo. I compared
the proliferation rate of the pMMR and dMMR clones and the growth rate as reflected in
the fold increase in pMMR cells compared to dMMR cells over 4 days was found not differ
significantly (Fig.3.3b).
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Figure 3.3. Inducing MMR deficiency in neuroblastoma mouse cancer cells and the
impact on growth in vitro.
(a) Neuro-2a cells were transfected with a CRISPR CAS9 knock-out plasmid specific for
the MLH1 gene. Expression of MLH1 in the parental cells and several putative knock-out
clones was analyzed by Western Blot. (b) WT neuro-2a cells (pMMR) (n=9) and MLH1
KO neuro-2a cells (dMMR) (n=9) were seeded and counted on day 0 and were counted
again on day 4 to analyze the fold increase of each cell line. Statistical analysis was
performed by unpaired two-tailed Student’s t-test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001,
**** p ≤ 0.0001, NS (not significant). Results are representative of 3 pooled experiments.
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3.4 Baseline tumour growth of pMMR and dMMR neuro-2a
cells was similar in immunodeficient mice
Previously, I showed that pMMR and dMMR neuro-2a cells have similar baseline
proliferation rates in vitro (3.3b). In order to test the baseline tumour kinetics of pMMR
and dMMR neuro-2a cells in vivo, these cells were injected into immunodeficient SHO
mice. SHO mice lack both mature B-cells and mature T-cells. Mice bearing pMMR or
dMMR tumours were injected subcutaneously at day 0 and left to grow for a 24-day
period. I found that baseline tumour kinetics of pMMR and dMMR neuro-2a cells in vivo
was not significantly different (Fig 3.4).
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Figure 3.4. Growth of pMMR and dMMR neuro-2a cells in immunodeficient mice
was not significantly different.
pMMR and dMMR neuro-2a cells were injected subcutaneously into immunodeficient
SHO mice and sacrificed when tumours reached ~1400 mm3 (a) n=5, n=5, (b) n=5, n=6,
pMMR and dMMRrespectively. Statistical analysis was performed by unpaired two-tailed
Student’s t-test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant).
Results are representative of 2 independent experiments.
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3.5 Inducing DNA-MMR deficiency results in an increased
anti-tumour response in immunocompetent mice
DNA-mismatch repair deficient tumours have an increased response rate to ICIs. As
previously shown (Fig.3.2) this is in large part because these tumours are both immune
cell-infiltrated and immune-inflamed. As such, they display high levels of T-cell markers
and T-cell activation markers. In order to study the effect of inducing MMR-deficiency in
an immunologically cold tumour (neuroblastoma), both pMMR and dMMR cells were
injected into immunocompetent A/J mice with a similar MHC background to the neuro-2a
cells (H-2K). Mice were either treated with PBS (control) or an anti-PD1 antibody as
described before. Inducing MMR deficiency generated a strong anti-tumour response and
significantly hindered tumour growth in immunocompetent mice (Fig.3.5.1a-c).
Interestingly, treating with anti-PD1 did not have a statistically significant added benefit in
inhibiting tumour growth. This shows that inducing MMR deficiency on its own can trigger
an immunogenic rejection of tumours in immune-competent mice. It is important to note
that dMMR tumour-bearing mice were only monitored for an 18-day period in this
experiment, with corresponding tumour volumes reaching ~300-600mm3. I therefore
decided to monitor dMMR tumour growth over a longer period of time (30-day period) in
order to study whether treating these highly unstable and potentially immunogenic tumours
with ICI would further hinder tumour growth over time (Fig.3.5.1d). Preliminary data
shows that inducing dMMR tumours stimulates an initial anti-tumour response. However,
after 20 days the majority of dMMR tumour bearing mice not receiving treatment reached
the maximally permitted tumour size, whereas most mice receiving the combination of
MMR induction and anti-PD1 treatment were still well below the ~1400mm3 tumour
volume end point (Fig.3.5.1d).

Finally, to study whether starting anti-PD1 treatment earlier could enhance the anti-tumour
response of mice bearing dMMR neuro-2a cells, immunocompetent A/J mice were given
the ICI treatment starting at day 7 post tumour injection (Fig.3.5.2a, b). Notably, this
resulted in the cure of 2 mice bearing dMMR tumours that were treated with α-PD1, and 1
additional mouse exhibiting a significantly reduced level of growth compared to pMMR
tumours receiving α-PD1 treatment. (Fig.3.5.2b). However, starting α-PD1 treatment at day
39

7 did not result in a statistically significant reduction in tumour growth when compared to
mice bearing dMMR tumours not receiving α-PD-1 treatment (Fig.3.5.2a, b). It is important
to note that these mice were only monitored for an 18-day period in this experiment, with
corresponding tumour volumes reaching ~300-500mm3. In future experiments, I will
monitor these mice for a longer period of time to see whether treating dMMR tumour
bearing mice with anti-PD1 starting at day 7 has any added benefit in inhibiting tumour
growth.
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Figure 3.5.1. Inducing tumour MMR deficiency results in increased anti-tumour
response.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS or the anti-PD1 treatment (250ug/100ul) and
were sacrificed at day 18. Experiments were conducted a total of 3 times. Mice were
grouped into pMMR no treatment, dMMR no treatment, pMMR treatment and dMMR
treatment groups, (a) n=5, n=4, n=5, n=4, (b) n=5, n=5, n=6, n=6 respectively, (c) n=5,
n=5, n=6, n=6 , (d) n=5, n=6, n=5, n=6 respectively. Statistical analysis was performed by
unpaired two-tailed Student’s t-test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001,
ns (not significant).
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Figure 3.5.2. A combination of inducing MMR-deficiency and treating with anti-PD1
immune checkpoint blockade starting at day 7 can cure a subset of mice.
Wild type and dMMR neuro-2a cells were injected subcutaneously into A/J mice and
injected i.p at days 7, 10 and 13 (a) with the control PBS (n=8, n=7), (b) and the treatment
anti-PD1 (250ug/100ul) (n=8, n=6), respectively. Results are representative of 2 pooled
experiments.

44

3.6 Combination of inducing MMR-deficiency and treating
with anti-PD1 prolongs survival of immune competent mice
DNA mismatch repair-deficient tumours respond favorably to immune checkpoint
inhibitors. I therefore wanted to study whether combining MMR-induction of an
immunologically cold tumour (neuroblastoma) along with treating with anti-PD1 could
prolong survival of immune-competent mice. pMMR and dMMR cells were injected into
A/J mice and treated at days 10, 13 and 16 with either the PBS (control) or an anti-PD1
antibody. Moreover, mice were sacrificed when their tumour volume reached ~1400mm3.
Notably, there was no significant survival advantage to inducing MMR-deficiency on its
own (Fig.3.6a). However, the combination of inducing MMR-deficiency along with
treating with anti-PD1 resulted in a significant increase in survival when compared to
pMMR bearing mice receiving ICI treatment (Fig.3.6a). This highlights the potential utility
of inducing MMR-deficiency to render cold tumours immunogenic and then treating with
immune checkpoint blockade.

I also studied the impact of inducing MMR-deficiency on the overall health of mice by
analyzing their body weight over time (Fig.3.6b). Mice bearing dMMR-deficient tumours
displayed no significant decreases of body weight over time, similarly to their pMMR
counterparts (Fig.3.6b).
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Figure 3.6. Inducing tumour MMR deficiency and treating with anit-PD1 increases
survival of mice.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed as mice reached ~1400 mm3. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=6, n=5, n=6. Statistical analysis was performed using the two-sided log-rank (MantelCox) test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant).
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3.7 DNA-mismatch repair deficient tumours express higher
levels of MHC-I in vitro
MHC-I is an antigen-presenting molecule critical for presenting peptides to T-cells and is,
therefore, an essential component of immunosurveillance10. Due to the heightened antitumour immunity against dMMR tumours, I speculated that an increase in MHC-I
expression on dMMR cells may contribute to immunogenicity. In order to analyze the
MHC-I expression on pMMR and dMMR tumours, neuro-2a cells were grown in culture
at 3 different time points (8, 9 and 10 weeks). pMMR and dMMR cells were first grown in
culture for 8 weeks. Cells were then stained for MHC-I and analyzed by flow cytometry.
dMMR cells had a higher mean fluorescence intensity (MFI) of MHC-I when compared to
mismatch repair proficient neuro-2a cells (Fig 3.7a). These cells were left to grow an
additional week in culture and MHC-I levels analyzed at the 9-week time point (Fig 3.7b).
dMMR tumours expressed a higher MFI of MHC-I than their pMMR neuro-2a counterparts
at this time point (Fig 3.7b). Finally, cells were left to grow for 10 weeks in vitro and
dMMR cells still expressed a higher MFI of MHC-I than mismatch repair-proficient neuro2a cells (Fig 3.7c).
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Figure 3.7. Inducing MMR-deficiency enhances MHC-I expression in neuro-2a cells.
pMMR and dMMR neuro-2a cells were grown for (a) 8 weeks (b) 9 weeks and (c) 10
weeks in vitro and the mean fluorescence intensity of MHC-I was quantified for 3 replicates
each (n=3). MFI values are representative of the median fluorescence intensity. Grey
histograms display unstained neuro-2a MHC-I expression and the red and blue histograms
show stained pMMR and dMMR MHC-I expression, respectively. Statistical analysis was
performed by unpaired two-tailed Student’s t-test. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001,
**** p ≤ 0.0001, ns (not significant). Results are representative of 2 (a) and 3 (b), (c),
pooled experiments.
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3.8 Colorectal cancer patients with highly microsatellite
instable tumours express higher levels of MHC-I related
genes
I showed that inducing dMMR in vitro results in a higher mean fluorescence intensity
(MFI) of MHC-I (Fig.3.7). We, therefore, set out to study whether such differences in
MHC-I levels existed in highly microsatellite-instable (MSI-h) human tumours when
compared to microsatellite-stable (MSS) samples using the COAD READ cohort of the
TCGA database. I found no differences in the gene expression (mRNA) levels of HLA-A
and HLA-B between the MSS and MSI-h tumour samples (Fig.3.8a, b). However, I found
that HLA-C transcript levels were significantly higher in MSI-h samples when compared
to MSS samples (Fig.3.8c). Importantly, I also found a significant increase in B2M
(which encodes the β2 microglobulin protein, a component of the MHC-I complex) gene
transcript levels in MSI-h tumour tissues when compared to MSS tumour tissues
(Fig.3.8d). These findings demonstrate that certain MHC-I-associated gene transcript
levels are upregulated in MSI-h samples when compared to MSS samples. This further
elucidates the increased immunogenicity of highly microsatellite-instable tumours when
compared to the less immunogenic microsatellite-stable tumours. In order to better
understand MHC-I expression in the context of an anti-tumour response, I originally set
out to analyze MHC-I expression of cells cultured from murine neuroblastoma tumours
grown in vivo. However, I ran into technical challenges as I could not acquire a GD2
(marker specific for neuroblastoma cells) specific antibody to analyze MHC-I expression
exclusively on tumour cells.
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Figure 3.8. MSI-h tumours express higher levels of MHC-I genes.
Normalized RNA-seq data for MHC-I genes HLA-A, HLA-B, HLA-C and B2M was
obtained from the TCGA database COAD READ dataset and grouped into normal, MSS
and MSI-h tissues (n=51, n=257, n=51). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤
0.0001, ns (not significant).
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3.9 Effect of inducing DNA-MMR repair in neuro-2a cells on
PD-L1 expression
I previously showed that inducing MMR-deficiency in neuro-2a cells results in an increase
in MHC-I expression (Fig.3.7). I next studied whether inducing such deficiency affects the
expression of PD-L1 on neuro-2a cells. PD-L1 is a marker that mediates
immunosuppression and tumours that express PD-L1 are more responsive to immune
checkpoint inhibitor treatment. Previous studies have shown the highly microsatellite
instable tumours (MSI-h), which respond well to ICI, express higher levels of PD-L1 when
compared to their microsatellite stable (MSS) counterparts 38. I again used the TCGA
COAD READ RNA-seq data to confirm this. I found that patients with MSI-h tumours
expressed higher levels of PD-L1 when compared to both MSS samples and normal
samples (Fig.3.9.1).
I then studied the effect of inducing MMR-deficiency on the expression of PD-L1 on neuro2a cells in vitro. pMMR and dMMR tumours, neuro-2a cells were grown in culture at 3
different time points (8, 9 and 10 weeks). I found that at 8 weeks, there was no significant
difference in PD-L1 expression between pMMR and dMMR neuro-2a cells (Fig.3.9.2a).
After 9 weeks and 10 weeks in culture, MMR-deficient neuro-2a cells had significantly
higher levels of PD-L1 protein compared to MMR-proficient neuro-2a cells (Fig.3.9.2b, c).
These findings support the observation of higher PD-L1 protein levels in MSI-h tumours
in patients24. More specifically, our results demonstrate an increase in PD-L1 protein level
after MMR deficiency is induced in vitro. This model, therefore, does not include immune
system pressures and therefore there may be another mechanistic reason for upregulation
of these molecules.
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Figure 3.9.1 MSI-h colorectal tumours express higher levels of PD-L1 mRNA.
Normalized RNA-seq data for CD274 (PD-L1) was obtained from the TCGA database
COAD READ dataset and grouped into normal, MSS and MSI-h tissues (n=51, n=257,
n=51). * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant).
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Figure 3.9.2 Effect of inducing MMR-deficiency on PD-L1 expression.
pMMR and dMMR neuro-2a cells were grown for (a) 8 weeks (b) 9 weeks and (c) 10
weeks in vitro and the mean fluorescence intensity of PD-L1 was quantified for 3
replicates each (n=3). MFI values are representative of the median fluorescence intensity.
Grey histograms display unstained neuro-2a MHC-I expression and the red and blue
histograms show stained pMMR and dMMR MHC-I expression, respectively. Statistical
analysis was performed by unpaired two-tailed Student’s t-test. * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant). Results are representative of 2 (a)
and 3 (b), (c), pooled experiments.
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3.10 Effect of inducing MMR-deficiency and treating with
anti-PD1 on T-cell infiltration of the tumour-draining lymph
nodes
I previously showed that inducing MMR-deficiency elicits an anti-tumour response that
hinders tumour growth (Fig.3.5.1). Moreover, MMR-deficient tumours are often highly
infiltrated with T-cells. I therefore wanted to explore whether inducing MMR-deficiency
and treating with anti-PD1 affected T-cell infiltration into tumour-draining lymph nodes. I
injected mice with either pMMR or dMMR neuro-2a tumour cells and treated tumourbearing mice with anti-PD1 at days 10, 13 and 16. Mice were then sacrificed on day 18 and
the tumour-draining lymph nodes from each group were pooled together. Cells isolated
from the lymph node were stained for T-cell markers and analyzed using multicolour flow
cytometry. My preliminary results show that dMMR tumours treated with anti-PD1 had
higher infiltration of T-cells (Fig.3.10). However, it is important to note that these results
are representative of a single experiment and that this experiment needs to be repeated with
additional control groups not treated with anti-PD1 antibody.
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Figure 3.10. Inducing MMR-deficiency enhances T-cell recruitment to tumour
draining lymph nodes in response to anti-PD1 treatment.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and treated
with anti-PD1 at days 10, 13 and 16. These cells were gated as a percentage of all live
single cells. Pooled lymph nodes were harvested, and T-cell populations were analyzed
by flow cytometry.
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3.11 T-cell infiltration into tumours in response to dMMR
induction and anti-PD1 treatment
I have shown that inducing MMR deficiency results in an increased anti-tumour response
(Fig.3.5). Moreover, dMMR tumours show increased T-cell infiltration (Fig.3.2). I
therefore injected mice with either dMMR or pMMR neuro-2a cells and treated with either
PBS or anti-PD1 antibody at days 10, 13 and 16. Mice were sacrificed at day 18 and
tumours were pooled together and stained for T-cell markers, analyzed using multicolour
flow cytometry. This experiment was conducted a total of 3 times (5-6 mice in each group),
with representative results from each separate experiment presented in the results below.
Note that each experiment will be represented as follows: experiment #1, experiment #2,
experiment #3.

In the first and third experiments, I found that dMMR tumours had higher percentages of
CD3+ cells than pMMR tumours in both the control (PBS treatment) and anti-PD1
treatment groups (Fig.3.11a, c). In the second experiment I found that dMMR tumours had
higher T-cell infiltration than pMMR tumours in the non-treatment PBS group. However,
in the anti-PD1 treated mice, dMMR tumours did not have significantly higher levels of Tcells when compared to pMMR tumours (Fig.3.11b). These results illustrate a trend of
higher T-cell levels in dMMR induced tumours when compared to pMMR tumours. This
may suggest that inducing MMR deficiency is stimulating an increased T-cell response into
neuroblastoma tumours.
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Figure 3.11. Effect of inducing MMR-deficiency on T-cell infiltration of mouse
neuroblastoma tumours.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage of live cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c) n=5, n=5, n=6, n=6 respectively. These cells
were gated as a percentage of all live single cells. Data represents technical replicates.
Statistical analysis was performed using one-way ANOVA. * p ≤ 0.05, ** p ≤ 0.01, *** p
≤ 0.001, **** p ≤ 0.0001, ns (not significant).
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3.12 CD8+ T-cell infiltration into tumours in response to
dMMR induction and anti-PD1 treatment
Cytotoxic T-cells play an essential role in the anti-tumour immune response. I therefore
studied the effect of inducing dMMR on the stimulation of CD8+ T-cells in mouse
neuroblastoma tumours with the same experimental setup as previously described (3.11).
This experiment was conducted a total of 3 times (with 5-6 mice in each group), with
representative results from each separate experiment presented in the results below. Note
that each experiment will be represented as follows: experiment #1, experiment #2,
experiment #3.

In my first experiment, I observed that tumours with induced MMR deficiency had
increased CD8+ T-cell infiltration compared to pMMR tumours (Fig.3.12a). Moreover,
dMMR tumours in the anti-PD-1 treatment groups also had higher levels of CD8+ T-cells
when compared to pMMR tumours from the anti-PD1 treatment group (Fig.3.12a).

The second and third experiments yielded similar results to the first. Specifically, dMMR
tumours again displayed an increased CD8+ T-cell infiltration compared to pMMR tumours
(Fig.3.12b, c). The same trends were observed in the anti-PD1 treatment groups (Fig.3.12b,
c).

These results suggest that inducing dMMR in neuroblastoma tumours may stimulate an
increase in CD8+ T-cell infiltration into these immunologically cold tumours.
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Figure 3.12. Effect of inducing MMR-deficiency on CD8+ T-cell infiltration into
mouse neuroblastoma tumours.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3 + cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c) n=5, n=5, n=6, n=6 respectively. These cells
were gated as a percentage of all live single cells. Data represents technical replicates.
Statistical analysis was performed using one-way Anova. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001, **** p ≤ 0.0001, ns (not significant).
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3.13 The effect of inducing MMR deficiency and treating with
anti-PD1 on T-cell activation and exhaustion
I previously showed that dMMR tumours are highly infiltrated with T-cells and show signs
of immune activation (Fig 3.2). I therefore wanted to study whether inducing dMMR in a
genomically-stable cold tumour (neuroblastoma) resulted in any differences in the
phenotype of T-cells isolated from tumours. I therefore injected pMMR and dMMR neuro2a cells into A/J mice and treated at days 10, 13 and 16 with either the PBS (control) or an
anti-PD1 antibody. I then euthanized mice at day 18, isolated T-cells from tumours as
described in the Materials and Methods section and analyzed them using flow cytometry.
This experiment was conducted 3 times, with experiments 1 and 3 generating results in
agreement with each another. However, experiment 2 showed conflicting data and,
therefore this experiment will be repeated in order to resolve the discrepancy. In experiment
1, I found that there were no significant differences in the levels of immune activation
markers between mice bearing either pMMR or dMMR tumours and without anti-PD-1
treatment (PBS-treated controls) (Fig.3.13a). Moreover, when mice bearing pMMR
tumours were treated with anti-PD1 there was a significant increase in the expression of
activation and exhaustion markers (Fig.3.13a). However, dMMR tumours in mice treated
with anti-PD-1 resulted in a significant decrease in the level of activation and exhaustion
markers when compared to pMMR tumours treated with anti-PD-1 (Fig.3.13a). These
findings are of interest as a decrease in exhaustion markers in dMMR tumours may be a
sign of effective antigen clearance39.

In the second experiment, I observed similar results for the levels of exhaustion markers in
the control, PBS treatment group (Fig.3.13b). For certain exhaustion markers I saw a slight
increase in level in the dMMR group (Fig.3.13b). However, in contrast to my first and third
experiments, there were higher levels of exhaustion markers in mice with dMMR tumours
receiving anti-PD-1 treatment.

Results of the third experiment (Fig.3.13c) were in agreement with the results of experiment
one (Fig.3.13a).
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Figure 3.13. Tumour infiltrating lymphocyte activation and exhaustion in mice
bearing induced DNA mismatch repair deficient tumours.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3+ cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c) n=5, n=5, n=6, n=6 respectively. These cells
were gated as a percentage of all live CD8+ T-cells. Data represents technical replicates.
Statistical analysis was performed using one-way Anova. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001, **** p ≤ 0.0001, ns (not significant).
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3.14 The effect of inducing MMR-deficiency and treating with
anti-PD1 blockade on T-cell cytotoxic activity
In the previous section (3.13), I showed the effect of inducing MMR-deficiency and treating
with anti-PD1 on T-cell activation and exhaustion. I next wanted to analyze the functional
activity of T-cells in response to MMR-induction and anti-PD1 treatment. As CD8+ T-cells
target cancer cells, they release cytolytic granules as an effector mechanism40. During this
process the granule membrane fuses with the cytoplasmic membrane and the result is the
expression of lysosomal associated proteins, such as CD107a, on the cell surface40. I
therefore studied the expression of CD107a on CD8+ T-cells from tumours of mice
following the same experimental setup as previous described (3.13).

In one set of experiments, I found there to be no significant differences in the expression
of CD107a on CD8+ T-cells in pMMR and dMMR tumour bearing mice receiving the
control PBS (Fig.3.14a). However, there was a significant increase in this degranulation
marker in mice bearing pMMR tumours and receiving anti-PD1 treatment (Fig.3.14a).
Moreover, the combination of dMMR induction and anti-PD1 did not increase CD107a
levels on CD8+ T-cells (Fig.3.14a).

In my second experiment, I found that mice bearing dMMR tumours receiving no treatment
expressed higher levels of the CD107a degranulation marker on CD8+ T-cells compared to
their pMMR counterparts (Fig.3.14b). The same result was observed in the anti-PD1
treatment group, as the dMMR bearing mice had higher levels of CD107a+CD8+ T-cells
than the pMMR tumour-bearing mice (Fig.3.14b).

Results for experiment 3 are similar to experiment 1, following the same trend in CD107a
expression (Fig.3.14c). Due to the conflicting results, this experiment needs to be repeated.
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Figure 3.14. CD8+ T-cell degranulation activity from tumours following MMRinduction and anti-PD1 treatment.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3 + cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c) n=5, n=5, n=6, n=6 respectively. These cells
were gated as a percentage of all live CD8+ T-cells. Data represents technical replicates.
Statistical analysis was performed using one-way Anova. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001, **** p ≤ 0.0001, ns (not significant).
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3.15 Effect of inducing MMR-deficiency and treating with
anti-PD1 on CD39+ PD1+ CD8+ T-cells infiltrated into
tumours
I previously analyzed a number of T-cell exhaustion markers from TILs isolated from
pMMR or dMMR tumours in control mice (PBS treatment) or being treating with anti-PD1
(Fig.3.11). Moreover, CD39 is an important molecule expressed on the surface of T-cells
which converts ATP to AMP41. Under inflammatory conditions, CD39 leads to the
production of immunosuppressive adenosines41. The expression of CD39 on T-cells has
been linked to T-cell exhaustion and dysfunction41. I therefore used the same experimental
setup as previously mentioned, and isolated T-cells from the tumours and stained for both
CD39 and the activation/exhaustion marker PD-1 (3.13).
In my first experiment, I found no significant differences in the CD8+ T-cell population coexpressing CD39 and PD1 (Fig.3.15a). Moreover, pMMR tumour bearing mice receiving
anti-PD1 treatment expressed significantly higher levels of CD39+PD1+CD8+ T-cells
(Fig.3.15a). However, the combination of dMMR and anti-PD1 treatment resulted in a
significant decrease in this exhausted T-cell population (Fig.3.15a).

In my second experiment, I found that dMMR tumour-bearing mice had slightly higher
numbers of CD39+PD1+CD8+ T-cells compared to pMMR tumour-bearing mice (control
groups, treated with PBS, in both cases) (Fig.3.15b). Moreover, this was observed in the
anti-PD1 treatment groups, with the dMMR tumour-bearing mice displaying higher levels
of CD39, PD1 double positive CD8+ T-cells (Fig.3.15b).

The third experiment (Fig.3.15c) yielded results similar to those of experiment one
(Fig.3.15a). Due to the conflicting nature of these results, this experiment needs to be
repeated.
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Figure 3.15. Tumour infiltrating lymphocyte exhaustion in mice bearing induced
DNA mismatch repair deficient tumours.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3 + cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c) n=5, n=5, n=6, n=6 respectively. These cells
were gated as a percentage of all live CD8+ T-cells. Data represents technical replicates.
Statistical analysis was performed using one-way Anova. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001, **** p ≤ 0.0001, ns (not significant).
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3.16 Effect of inducing MMR-deficiency and treating with
anti-PD1 on stimulating immunosuppressive T-regulatory
cells in tumours
T-regulatory T-cells are an important immunosuppressive population that dampens the
immune response. These cells play an important role in immune escape. I therefore wanted
to study whether the superior anti-tumour immune response against dMMR tumours
(Fig.3.6) could be explained by less infiltration of Tregs into these tumours. Following the
same experimental strategy as previously described (3.13), mice were euthanized on day
18 and stained for the Treg cell markers CD4+ and CD25+. I conducted 3 experiments in
total with varying results. I found that in experiment 1 (Fig.3.16a) there were no significant
differences in the Treg population in between pMMR and dMMR tumour-bearing mice
receiving the control PBS. There was also no difference in the Treg populations between
pMMR and dMMR tumour bearing mice treated with anti-PD-1. Moreover, in experiment
2 (Fig.3.16b), there were no significant differences in Treg percentages in response to
induced dMMR, either in control mice (PBS-treated) or after anti-PD-1 treatment: however,
anti-PD-1 treatment resulted in a slight but significant increase in Tregs in mice with both
pMMR and dMMR tumours. The third experiment yielded the same significant increase in
Tregs in response to anti-PD-1 treatment in mice with dMMR tumours, but no difference
in Tregs between PBS-treated mice with pMMR and dMMR tumours and no difference in
Tregs between anti-PD-1-treated mice with pMMR and dMMR tumours.

Overall, this experiment requires repetition with a strategy that achieves higher n values
than those indicated in Figure 3.15. The low n used to obtain the data shown does not
generate sufficient statistical power to yield interpretable results. In addition, FOXP3 needs
to be incorporated into this staining, in order to properly identify T-reg cells. Nevertheless,
these preliminary results suggest that Tregs cells may not play a significant role in the antitumour response elicited against dMMR tumours.
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Figure 3.16. T-regulatory cell infiltration into pMMR and dMMR tumours.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3 + cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR + PBS
treatment (control), dMMR + PBS treatment (control), pMMR + anti-PD-1 treatment, and
dMMR + anti-PD-1 treatment groups, (a) n=5, n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c)
n=5, n=5, n=6, n=6 respectively. These cells were gated as a percentage of all live CD3+
cells. Data represents technical replicates. Statistical analysis was performed using oneway Anova. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant).
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3.17 Effect of inducing MMR deficiency and treating with
anti-PD1 on CD4+ T-cell activation and exhaustion
I previously studied CD8+ T-cell exhaustion (Fig.3.13). I next set out to investigate whether
inducing MMR deficiency affects CD4+ T-cell activation and exhaustion and whether antiPD1 further impacts CD4+ T-cell exhaustion. CD4+ T-cells are an important subset of cells
that can directly target cancer cells or act as “helper cells” and aid in the activation of
cytotoxic CD8+ T-cells42. Exhaustion of such cells can lead to a weakened anti-tumour
response42. I therefore studied the effect of inducing dMMR on CD4+ T-cell exhaustion,
following the same experimental design used to generate the data shown in Figure 3.13. I
first analyzed the levels of the immune checkpoint molecule CTLA4, which plays a role in
hindering T-cell activation42. As T-cells become activated and exhausted they express
higher levels of CTLA442. This experiment was repeated 3 times, and over the 3
experiments I did not see any significant differences in CTLA4 expression on CD4+ T-cells
in response to MMR induction (Fig.3.17a).
I next set out to study the levels of the PD-1 immune checkpoint molecule on CD4+ T-cells
in pMMR and dMMR tumours (Fig.3.17b). In my first and third experiments I found a
lower percentage of CD4+ T-cells that express PD-1 in dMMR tumours in both the groups
treated with PBS and anti-PD1 (Fig.3.17b). However, this was not observed in experiment
2 (Fig.3.17b).

Moreover, exhausted T-cells often co-express multiple immune checkpoint molecules. I
therefore studied populations of CD4+ T-cells that co-express the PD-1 and TIM-3 immune
checkpoint molecules. In experiments 1 and 3, I found that dMMR tumours in both the
non-treatment and the anti-PD1 treatment groups had a lower percentage of CD4+ T-cells
that co-expressed these exhaustion markers (Fig.3.17c). However, in experiment 2 I found
conflicting results, and this experiment therefore needs to be repeated (Fig.3.17c).

80

81

Figure 3.17. CD4+ T-cell exhaustion in pMMR and dMMR tumours.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3 + cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, (a) n=5,
n=4, n=5, n=4 (b) n=5, n=5, n=6, n=6, (c) n=5, n=5, n=6, n=6 respectively. These cells
were gated as a percentage of all live CD4+ T-cells. Data represents technical replicates.
Statistical analysis was performed using one-way Anova. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤
0.001, **** p ≤ 0.0001, ns (not significant).

82

3.18 A combination of inducing MMR-deficiency and antiPD1 treatment results in a significant decrease in
dysfunctional T-cells
I have shown the effect of inducing MMR deficiency and treating with anti-PD1 on CD8+
T-cell exhaustion. Another important subset of CD8+ T-cells are dysfunctional CD38+PD1+CD8+ T-cells43. More recently, studies have shown that these cells are generated when
tumours are not properly primed with antigens prior to anti-PD1 treatment43. I therefore
wanted to investigate whether dysfunctional T-cells are upregulated in a similar manner in
this study. This model incorporates MMR-proficient (pMMR) tumours, which have a low
tumour mutational burden and therefore would not be considered antigenically primed.
Moreover, this model also includes MMR deficient (dMMR) tumours which, in theory,
have a higher tumour mutational burden and would be considered antigenically primed. I
followed the same experiment strategy as used to generate the data shown in Figure 3.13.
Similar to the study conducted by Verma et al. I did not find any significant differences in
the percentage of dysfunctional CD38+PD-1+CD8+ T-cells from both poorly antigenically
primed and antigenically primed tumours (pMMR and dMMR) (Fig.3.17). However, I
found a significant increase in this dysfunctional population in the potentially nonantigenically primed genomically stable pMMR tumours receiving anti-PD1 treatment
(Fig.3.18). Interestingly, dMMR tumours, which are genomically unstable and theoretically
antigenically primed, showed a significant decrease in their dysfunctional CD38+PD1+CD8+ T-cell population (Fig.3.18). These observations are similar to what has been
observed by Verma et al. and underscore the potential importance of combining MMR
induction along with PD-1 blockade in order to properly prime tumours before anti-PD1
treatment to reduce T-cell dysfunction and resistance to anti-PD1 therapy. It is important
to note that these results are preliminary, and this experiment needs to be repeated to further
validate these findings.
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Figure 3.18. A combination of MMR-induction and anti-PD1 treatment results in a
decrease in dysfunctional T-cells.
pMMR and dMMR neuro-2a cells were injected subcutaneously into A/J mice and injected
i.p at days 10, 13 and 16 with the control PBS and the treatment anti-PD1 (250ug/100ul)
and were sacrificed at day 18. Tumours from each treatment group were pooled together.
Cells from the tumour single cell suspension were stained with a live/dead dye and live,
singlet, lymphocytes were gated. Cells are presented as a percentage CD3 + cells. Results
are representative of 3 independent experiments. Mice were grouped into pMMR no
treatment, dMMR no treatment, pMMR treatment and dMMR treatment groups, n=5, n=5,
n=6, n=6 respectively. These cells were gated as a percentage of all live CD8+ T-cells. Data
represents technical replicates. Statistical analysis was performed using one-way Anova. *
p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, ns (not significant).
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3.19 Immune markers associated with improved overall
survival in high-risk neuroblastoma patients
I previously showed that inducing dMMR in immunologically cold murine neuroblastoma
tumours, stimulates an anti-tumour immune response characterized by a slower tumour
growth rate (Fig.3.5.1). Moreover, I have also shown that this enhanced immune response
in dMMR neuroblastoma tumours is accompanied by higher T-cell infiltration (Fig.3.11)
and higher CD8+. T-cell infiltration (Fig.3.12). I next aimed to study whether the
expression of immune markers in neuroblastoma patient tumours had any effect on
overall survival. I computationally mined the TARGET database, which focuses on
sequencing hard to treat high-risk neuroblastoma patients who have a worse clinical
outcome. I found that CD3 and CD4 immune markers were not associated with improved
prognosis. Interestingly, CD8 gene expression was associated with a statistically
significant improved overall survival of high-risk neuroblastoma patients. CD8+ T-cells
are effector cells that play an important role in the anticancer immune response.
Moreover, CD8+ T-cells are a major target of anti-PD1 immune checkpoint inhibitor
treatment. Here, I show the impact of CD8 gene expression in the immunologically cold
neuroblastoma tumours, on the overall survival of patients. Moreover, I have also shown
that by inducing dMMR in murine neuroblastoma tumours, this induces higher CD8+ Tcell infiltration. This is notable because, here I show that CD8 gene expression is
associated with improved prognosis in high-risk neuroblastoma patients.
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Figure 3.19. CD8a expression is associated with improved overall survival in highrisk neuroblastoma patients.
Overall survival of high-risk neuroblastoma patients stratified according to gene
expression of immune markers (a) CD3G, (b) CD4, (c) CD8a. Statistical analysis was
performed using the 2-sided log-rank test. Blue = overall survival of patients with gene
expression in the upper 30th quartile, Orange = overall survival of patients with gene
expression in the lower 30th quartile. Shaded areas represent pointwise 95% confidence
intervals.
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Chapter 4
Discussion
Over the past decade there has been a shift in oncology to move from only using radiation,
chemotherapy and surgery, to utilizing drugs that can mobilize the immune system to
recognize and target tumours27. These therapies include immune checkpoint inhibitors
(ICIs) that can bind to “immune checkpoint” molecules which serve to dampen the immune
response, re-invigorating anti-tumour T-cells27. Patients that respond to ICIs often show
durable remissions with improved overall survival44. However, the majority of patients still
do not respond to ICIs10. Many factors influence response to ICIs; however, it has become
evident that the immunological tumour microenvironment can both limit and promote ICI
response27. “Hot” tumour microenvironments tend to be heavily infiltrated with immune
cells and show signs of T-cell activation. As such, when patients with hot tumours are
treated with ICIs, the pre-existing T-cells in the tumour become re-invigorated and these
patients respond better to ICI treatment27. More recently, the TMB has become an important
biomarker of a “hot” tumour microenvironment10. Patients with a higher TMB accumulate
more mutations that produce foreign peptides, which allow the tumour to be detected as
non-self10. This consequently results in more T-cell infiltration into the tumour and better
response to ICIs10. An important group of patients with high TMB are a subset of patients
with microsatellite instability arising from MMR deficiency10. In this thesis, I therefore
wanted to explore whether inducing a deficiency in DNA-MMR repair, in an
immunologically cold tumour, could turn this tumour “hot” and induce an anti-tumour
immune response. Moreover, I also wanted to investigate whether inducing DNA-MMR
deficiency could further sensitize these tumours ICIs.

Over the past few years, MMR-deficiency and ICI treatment has been studied by a number
of groups. Germano et al. showed that inducing DNA-MMR deficiency in murine
colorectal and pancreatic cell lines, hindered tumour growth in immune competent mice33.
Their MMR-deficient cells were left to grow in vitro for ~133 days to accumulate mutations
and were injected into immunocompetent mice33. They observed a significant decrease in
tumour growth when compared to mice injected with the control cells 33. In this model, I
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similarly induced MMR-deficiency by generating an MLH1 KO cell line (Fig.3.3a).
However, I chose to study neuroblastoma, a solid tumour associated with a highly
immunosuppressive tumour microenvironment that is refractory to ICI. Similarly, I
observed that inducing MMR-deficiency in neuro-2a cells generated a stronger immune
response in immune competent mice when compared to the control MMR-proficient cells
(Fig.3.5). However, this level of immunogenicity was attained after leaving cells to grow
for only ~56 days in vitro. Moreover, mice injected with MMR-deficient cells that also
received anti-PD1 treatment showed a slight decrease in tumour growth when compared to
dMMR tumour bearing mice from the non-treatment group, however, this difference was
not significant. It is important to note that I could not show that inducing MMR deficiency
further sensitized mice to ICI after 18 days in vivo. However, I monitored dMMR induced
tumours for a longer period of time in order to study a potential added benefit to treating
with anti-PD1. I also conducted a survival experiment in order to investigate the overall
survival benefit of inducing MMR deficiency and treating with anti-PD1. Mice were
monitored for over 30 days and I showed that the combination of inducing MMRdeficiency in neuro-2a cell line and treating with anti-PD1 significantly prolongs mouse
survival when compared to mice bearing MMR proficient tumours treated with antiPD1(Fig.3.6a).

I also studied the immunogenic phenotype of both pMMR and dMMR tumours for any
underlying differences in immunogenicity prior to tumour injection into immune competent
mice and found that dMMR tumours express higher levels of MHC-I in vitro (Fig.3.7). I
further mined the TCGA database and similarly found that in the COAD READ cohort,
MSI-h patients who often have a deficiency in their DNA-MMR machinery, displayed
higher levels of certain MHC-I related genes when compared to MSS tumour samples
(Fig.3.8). Interestingly, I also found that dMMR tumours express higher levels of PD-L1
in vitro (Fig.3.9.2), similar to immunogenic MSI-h patients’ tumours (3.9.1). However, this
finding was in vitro and there may be other mechanistic differences to explain this increase
in PD-L1 expression.
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To my knowledge, this is the first study of the immune phenotype associated with an
increased anti-tumour response in induced dMMR tumour bearing mice. My preliminary
data shows that dMMR mice receiving anti-PD1 treatment showed a higher infiltration of
CD8+ T-cells into tumour draining lymph nodes when compared to pMMR tumour bearing
mice. Moreover, I also studied the T-cell phenotype in tumours and found that dMMR
bearing mice had higher levels of both T-cells and CD8+ T-cells when compared to pMMR
tumour bearing mice. These findings are in agreement with a dMMR induced model by
Mandal et al, where they targeted the DNA-MMR repair gene MSH2 (as opposed to MLH1)
and showed higher T-cell infiltration in dMMR induced tumours46. This finding is
important as I also show that CD8 gene expression in neuroblastoma patients is associated
with improved survival. Therefore, this increase in CD8+ T-cell infiltration in response to
dMMR is particularly significant in our neuroblastoma model, as we show that
neuroblastoma patients with higher CD8 gene expression have a better prognosis.

In addition to altered numbers of T-cells, I also examined T-cell exhaustion, which is
characterized by increased immune checkpoint expression and reduced T-cell function,
which limits the T-cell response against tumours. Specifically, I studied the expression of
a number of immune checkpoint molecules on CD8+ T-cells from pMMR tumours and
dMMR tumours in order to establish any differences in T-cell exhaustion in these
immunologically distinct tumours. Interestingly, I did not find a significant difference in
T-cell exhaustion in pMMR and dMMR tumours not receiving treatment (Fig.3.13a, c).
However, in 2 of my experiments I found that mice receiving a combination of MMR
induction and anti-PD1 treatment had lower levels of T-cell exhaustion when compared to
pMMR tumours (Fig.3.13a, c). Studies have shown that effective antigen recognition and
clearance results in lower T-cell exhaustion levels39. This combination of inducing MMRdeficiency, resulting in a potential increase in neoantigens, and then treating with anti-PD1
could reduce T-cell exhaustion. It is important to note that a third experiment showed
conflicting results, and this therefore needs to be repeated (Fig.3.13b). Finally, I studied the
CD4+ T-cell phenotype in response to MMR induction and anti-PD1 treatment. In order to
study exhaustion, I analyzed expression of immune checkpoint molecules such as CTLA4, PD-1 and TIM-3. Consistent with my previous findings, there were only slight difference
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in the expression of immune checkpoint molecules in CD4+ T-cells from pMMR or dMMR
tumours not receiving treatment. Interestingly, I found that pMMR bearing mice treated
with anti-PD1 display an increase in CD4+ T-cell exhaustion, however combining MMRinduction of neuroblastoma tumours in combination with anti-PD1 results in a decrease in
T-cell exhaustion.

Finally, I aimed to study the dysfunctional T-cell phenotype in MMR-induced tumours
treated with anti-PD1. Dysfunctional T-cells are an important population of T-cells that
often hinder anti-tumour immunity and can lead to resistance to anti-PD1 therapy43. A study
conducted by Verma et al showed that treating with anti-PD1 prior to antigenically priming
tumours results in a significant increase in the CD38+PD-1+CD8+ dysfunction T-cell
population43. However, they showed that vaccinating mice in order to prime these tumours
with antigen prior to anti-PD1 treatment resulted in a significant decrease in these
dysfunctional T-cells43. In this model, preliminary results similarly demonstrate that
inducing MMR-deficiency in order to antigenically prime immunologically cold
neuroblastoma tumours and then treating with anti-PD1 results in a significant decrease in
dysfunctional T-cells when compared to pMMR tumours receiving anti-PD1 treatment.

In this study, I have established key differences in the T-cell immune phenotype in tumours
between pMMR and dMMR tumour bearing mice receiving no treatment and receiving
anti-PD1 treatment. It is important to note that the experiments characterizing changes in
T-cell phenotype need to be repeated, as one of my experiments showed conflicting results.
Additionally, in my future studies I will aim to not only establish differences in the T-cell
phenotype from pMMR and dMMR tumour bearing mice, but also whether these T-cells
differ in their cytotoxic capabilities. Another limitation of my study is that all my in vivo
experiments utilized a subcutaneous model for neuroblastoma tumour growth in mice.
Although, this model allows for tumours to be readily measured, this does have its
limitations as neuroblastoma tumours in patients grow in the adrenal medulla. The
subcutaneous tumour microenvironment therefore does not accurately represent the
complex architecture associated with tumour growth in the adrenal medulla. However,
orthotopic injections into the adrenal medulla are technically challenging and were
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therefore difficult to implement for my experiments. Moreover, another technical challenge
in this study is that the generation of random neoantigens, which can be quite immunogenic,
can induce a strong anti-tumour response in the absence of any treatment. This is a technical
challenge in this project, as I grow the cells in culture for injection into mice, they can
develop random mutations that can render them more or less immunogenic because of the
induced mismatch repair deficiency. This phenomenon has been also reported in other
cancer models with higher TMB34. In my future studies, I aim to repeat my in vivo tumour
growth experiments, however, I will culture the neuroblastoma cells over a longer period
of time in vitro in order to investigate whether this leads to an increase in neoantigen
production and a heightened anti-tumour response once injected into immune competent
mice.

Immune checkpoint inhibitors have improved the survival of many cancer patients over the
years. However, a major challenge in treating patients with “cold tumours” is the poorly
immunogenic tumour microenvironment. To my knowledge, this study is the first to show
that inducing MMR-deficiency in the poorly immunogenic, ICI refractory murine
neuroblastoma tumours, as a mechanism to render these tumours immunologically “hot”,
results in a heightened anti-tumour response in immune competent mice. My data also
demonstrates that inducing MMR-deficiency in poorly immunogenic neuroblastoma
tumours and treating with anti-PD1 prolonged survival of mice. Neuroblastoma tumours
are highly immunosuppressive, and this study demonstrates the potential of inducing
MMR-deficiency in these tumours to overcome their highly tumour suppressive TME and
further sensitize these tumours to ICI treatment. This study also provides a mechanistic
understanding of the impact of inducing MMR-deficiency and treating with anti-PD1 on
T-cell exhaustion and dysfunction.
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